This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
FRA:GU5's Price-to-Median-PS-Value is ranked better than 80% of 70
companies
in the Medical Distribution industry
Industry Median: 0.795
vs FRA:GU5: 0.53
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.55
/
2.91
=
0.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Median PS Value Related Terms
Guangzhou Baiyunshan Pharmaceutical Holdings Co Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Median PS Value Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
FRA:GU5 vs MCK, COR, CAH: Median PS Value Comparison
For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Price-to-Median-PS-Value vs Medical Distribution Industry
10-Year Median PS Ratio is 0.4943.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.887.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) has a Median PS Value of €2.91 as of Jun. 28, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. This is 439% above median its historical median of 0.54. Over the past decade, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Median PS Value has ranged from 0.35 to 1.23. According to the industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #14 out of 70 companies in the Medical Distribution industry, placing it in the top 20%.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Median PS Value too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Median PS Value of €2.91 is 439% above median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 1.23. Based on the distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #14 out of 70 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Median PS Value compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Guangzhou Baiyunshan Pharmaceutical Holdings Co ranks #14 out of 70 companies for Median PS Value. This places Guangzhou Baiyunshan Pharmaceutical Holdings Co in the top 20% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.80. Historically, Guangzhou Baiyunshan Pharmaceutical Holdings Co's own Median PS Value has ranged from 0.35 to 1.23 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Distribution company?
The median Median PS Value among Medical Distribution companies is 0.80, based on 70 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. For the Medical Distribution industry, the median Median PS Value is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Median PS Value is €2.91, which is 439% above median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.30, compared to a current price of €1.55 — trading 32.6% below its estimated fair value. The current Median PS Value is €2.91, which is 439% above median its 10-year median of 0.54. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5), the current Median PS Value is €2.91 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (FRA:GU5) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of €1.55 is trading 32.6% below its estimated GF Value™ of €2.30.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for FRA:GU5:
Median PS Value: €2.91 (439% above median its 10-year median of 0.54)
GF Value™: €2.30 vs. price of €1.55 (32.6% below fair value)
No single metric tells the full story. See the FRA:GU5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
71GF Score
Get the complete analysis for FRA:GU5
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GU5 has been successfully added to your 
